|
81
|
Baricitinib (Olumiant®) and increased risk of diverticulitis: Recommendations for Healthcare Professionals from the SFDA
|
|
Precautions
|
|
|
76
|
Safety Signal of Cardiac Failure associated with the use of Ibrutinib
|
|
Signal
|
|
|
74
|
Switching between Warfarin Brands and The Importance of Close Monitoring of INR
|
|
Precautions
|
|
|
73
|
Hydroxychloroquine and Chloroquine Alone and in Combination with Azithromycin and Potential Increased Risk of Heart Rhythm Problems
|
|
Warning
|
|
|
72
|
SFDA Recommendations for Healthcare Professionals Regarding The Unapproved Use of Hydroxychloroquine and Chloroquine in Treatment of COVID-19
|
|
Warning
|
|
|
71
|
SFDA Advises Continued Use of Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARBs) in Patients with COVID-19
|
|
Precautions
|
|
|
70
|
SFDA’s Advice on the Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in Patients with COVID-19
|
|
Precautions
|
|
|
77
|
Safety Signal of Baricitinib and the Potential Risk of Diverticulitis
|
|
Signal
|
|
|
69
|
Risk of potentially fatal respiratory depression with benzodiazepines and opioids
|
|
Warning
|
|
|
68
|
Concern on Potential Risk of Respiratory Depression Associated with Gabapentinoids (pregabalin and gabapentin) medications
|
|
Warning
|
|
